

## WHO WE ARE

LUNAC Therapeutics is a UK-based drug discovery company focused on the development of advanced life-saving anticoagulants.

We are progressing a next generation oral anticoagulant for the treatment and prevention of life-threatening thrombotic events, while removing associated bleeding risks.

## OUR SCIENCE

Oral anticoagulants can be life-saving drugs in cases of thrombosis, however current therapies present clinicians and patients with a difficult choice: anticoagulation efficacy **OR** an increased risk of bleeding.

Our first-in-class, oral small molecule that targets activated **Factor XII (FXIIa)**, an enzyme which plays a key role in clot formation but not in the normal stemming of bleeding. Individuals who have had Factor XII inhibited, unlike any other coagulation protease, do not exhibit any abnormal bleeding.

By breaking the link between efficacy and risk of bleeding, we aim to provide a paradigm shift in the prevention of thrombosis.



**87 million people**

currently suffer worldwide from leading thrombosis-causing diseases

Source: Decision Resources Group



Indications treated by anti-coagulants are expected to result in a

**\$26 billion**

market globally by 2026



Blood clots (thrombosis) adversely affect **millions of people**



**1 in 4 people**

die from causes related to blood clots, despite current best practice



Venous thromboembolism is the

**#1 cause**

of preventable deaths in hospital

Source: Thrombosis Society UK

## OUR HISTORY AND EXPERTISE

LUNAC is a spin-out company from the **University of Leeds, UK**, founded and supported by **world-leading experts in blood coagulation**.

Our science built on a decade of academic research into FXIIa in association with some of the world's leading supporters of scientific and medical research, including the **Wellcome Trust, British Heart Foundation and the UK's Medical Research Council**.



**UNIVERSITY OF LEEDS**

### SCIENTIFIC FOUNDERS



**Professor Helen Philippou**

Professor of Translational Medicine, Faculty of Medicine and Health, University of Leeds



**Dr Richard Foster**

Associate Professor, Faculty of Engineering and Physical Sciences, University of Leeds

### OUR LEADERSHIP



**Julian Howell**  
CEO of LUNAC



**Dr Mervyn Turner**  
Chairman of the Board

Together, the LUNAC team and their advisors have discovered in excess of **30 development candidates** and taken multiple products through development, approval and into commercialization.

We are also supported by our lead investors:



Start Up of the Year Award

**WINNER**



[lunactherapeutics.com](http://lunactherapeutics.com)

@LUNACTx1

LUNAC Therapeutics